Adverse Effects in Patients with Intellectual and Developmental Disabilities Hospitalized at the University Clinical Hospital
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Target Population and Patients under Study
2.3. Case Definition
2.4. Selection Criteria and Sample Size
2.4.1. Inclusion Criteria
2.4.2. Exclusion Criteria
2.5. Study Variables
2.5.1. Variables Linked to Care or Assistance
2.5.2. Variables Linked to the Illness or Condition
2.5.3. Variables Linked to the PwIDD
2.5.4. Variables Linked to Impact
2.6. Measurement Tools
2.7. Data Analysis
2.8. Ethical Considerations
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Reason, J. Human Error; Cambridge University Press: Cambridge, UK, 1990. [Google Scholar]
- Reason, J. Human error: Models and management. BMJ 2000, 320, 768–770. [Google Scholar] [CrossRef] [Green Version]
- Brennan, T.A.; Leape, L.L.; Laird, N.M.; Hebert, L.; Localio, A.R.; Lawthers, A.G.; Newhouse, J.P.; Weiler, P.C.; Hiatt, H.H. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N. Engl. J. Med. 1991, 324, 370–376. [Google Scholar] [CrossRef] [Green Version]
- World Health Organisation. Word Alliance for Patient Safety Progress Report: 2006–2007. Available online: http://www.who.int/patientsafety/infomation_centre/documents/progress_report_2006-2007.pdf (accessed on 6 June 2022).
- World Health Organisation. Word Alliance for Patient Safety Foward Program 2008–2009. Available online: http://www.who.int/patientsafety/infomation_centre/report/Alience_Programme 2008.pdf (accessed on 6 June 2022).
- Patient safety in Europe Baseline regional survey 2004-2005 data: Scherfigsvej 8, DK-2100 Copenhagen Ø, Denmark. Available online: www.euro.who.int (accessed on 6 June 2022).
- European Commission, DG Health and Consumer Protection. Patient Security: Marking Happen. Luxembourg, 5 April 2005. Available online: http://cpme.dyndns.org:591/database/luxembourg%Declaration%20on%20Ptient%20Safety%2005042005.pdf (accessed on 8 June 2022).
- Bates, D.W.; Cohen, M.; Leape, L.L.; Overhage, J.M.; Shabot, M.M.; Sheridan, T. Reducing the frequency of errors in medicine using information technology. J. Am. Med. Inform. Assoc. 2001, 8, 299–308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ministry of Health and Consumption, Quality Agency of the National Health System. Quality Plan for the National Health System; Ministry of Health and Consumption: Madrid, Spain, 2007.
- Wagar, E.A.; Yuan, S. The laboratory and patient safety. Clin. Lab. Med. 2007, 27, 909–930. [Google Scholar] [CrossRef] [PubMed]
- Kalra, J. Medical errors: Impact clinical laboratories and other critical areas. Clin. Biochem. 2004, 37, 1052–1062. [Google Scholar] [CrossRef]
- Dighe, A.S.; Rao, A.; Coakñey, A.B.; Lewandrowski, K.B. Analysis of laboratory critical value reporting at a large academic medical center. Am. J. Clin. Pathol. 2006, 125, 758–764. [Google Scholar] [CrossRef]
- National Study on Adverse Effects Linked to Hospitalization (ENEAS). Madrid: Ministry of Health and Consumption, Report 2006. Available online: https://seguridaddelpaciente.es/resources/contenidos/ castellano /2006/ENEAS.pdf (accessed on 25 March 2022).
- Aibar, C.; Aranaz, J. Can adverse events related to healthcare be avoided? Ann. Navar. Health Syst. 2003, 26, 195–209. [Google Scholar]
- United Nations Convention on the Rights of Persons with Disabilities. UN. 2006. Available online: https://www.un.org/esa/socdev/enable/documents/tccconvs.pdf (accessed on 8 June 2022).
- O’Hara, J. Attending to the health needs of people with intellectual disability: Quality standards. Public Health Mex. 2008, 50 (Suppl. S2), s154–s159. [Google Scholar] [CrossRef] [PubMed]
- Allerton, L.A.; Welch, V.; Emerson, E. Health inequalities experienced by children and young people with intellectual disabilities: A review of literature from the United Kingdom. J. Intellect. Disabil. 2011, 15, 269–278. [Google Scholar] [CrossRef] [PubMed]
- Roberts, A.; Townsend, S.; Morris, J.; Rushbrooke, E.; Greenhill, B.; Whitehead, R.; Matthews, T.; Golding, L. Treat me right, treat me equal: Using national policy and legislation to create positive changes in local health services for people with intellectual disabilities. J. Appl. Res. Intellect. Disabil. 2013, 26, 14–25. [Google Scholar] [CrossRef] [PubMed]
- Oulton, K.; Sell, D.; Gibson, F. “LEARN”ing what is important to children and young people with intellectual disabilities when they are in hospital. J. Appl. Res. Intellect. Disabil. 2018, 31, 792–803. [Google Scholar] [CrossRef] [PubMed]
- Erickson, S.R.; Kamdar, N.; Wu, C.H. Adverse Medication Events Related to Hospitalization in the United States: A Comparison between Adults with Intellectual and Developmental Disabilities and Those Without. Am. J. Intellect. Dev. Disabil. 2020, 125, 37–48. [Google Scholar] [CrossRef] [PubMed]
- Carletta, J. Assessing agreement on classification tasks. Kappa Statisticsc. Comput. Linguist. 1996, 22, 249–254. [Google Scholar]
- Lukasson, R.; Borthwick Duffy, S.; Buntix, W.H.E.; Coulter, D.L.; Craig, E.M.; Reeve, A.; Schalock Robert, L.; Snell Martha, E.; Spitalnik Deborah, M.; Spreat, S.; et al. Mental Retardation: Definition, Clasification and Systems of Supports, 10th ed.; American Association on Mental Retardation: Washington, DC, USA, 2002. [Google Scholar]
- Hernández-Milagro, M.A.; Rodríguez-García, G.T.; Gerona-Galdame, P. Disability in Spain. Assessment and guidance teams. Benefits. Assessment of disability due to dysfunction of the musculoskeletal and nervous system. Rehabilitation 2008, 42, 276–286. [Google Scholar] [CrossRef]
- Leape, L.I.; Brennan, T.A.; Laird, N.M.; Hebert, L.; Localio, A.R.; Lawthers, A.G.; Newhouse, J.P.; Weiler, P.C.; Hiatt, H.H. Incidence of adverse events and negligence in hospitalized patients: Results of the Harvard medical practice study II. N. Engl. J. Med. 1991, 324, 377–384. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wilson, R.M.; Runciman, W.B.; Gibberd, R.W.; Harrison, B.T.; Newby, L.; Hamilton, J.D. The Quality in Australian Health Care Study. Med. J. Aust. 1995, 163, 458–471. [Google Scholar] [CrossRef] [PubMed]
- Vincent, C.; Neale, G.; Woloshynowych, M. Adverse events in British hospitals: Preliminary retrospective record review. BMJ 2001, 322, 517–519. [Google Scholar] [CrossRef] [Green Version]
- Schiøler, T.; Lipczak, H.; Pedersen, B.L.; Mogensen, T.S.; Bech, K.B.; Stockmarr, A.; Svenning, A.R.; Frølich, A. Danish Adverse Event Study. Forekomsten af utilsigtede haendelser på sygehuse. Ugeskr. Læger 2001, 163, 5370–5378. [Google Scholar]
- Davis, P.; Lay-Yee, R.; Schug, S.; Briant, R.; Scott, A.; Johnson, S.; Bingley, W. Adverse events regional feasibility study: Indicative findings. N. Z. Med. J. 2001, 114, 203–205. [Google Scholar]
- Baker, G.R.; Norton, P.G.; Flintoft, V.; Blais, R.; Brown, A.; Cox, J.; Etchells, E.; Ghali, W.A.; Hébert, P.; Majumdar, S.R.; et al. The Canadian Adverse Events Study: The incidence of adverse events among hospital patients in Canada. CMAJ 2004, 170, 1678–1686. [Google Scholar] [CrossRef] [Green Version]
- Forster, A.J.; Asmis, T.R.; Clark, H.D.; Al Saied, G.; Code, C.C.; Caughey, S.C.; Baker, K.; Watters, J.; Worthington, J.; van Walraven, C. Ottawa Hospital Patient Safety Study. Ottawa Hospital Patient Safety Study: Incidence and timing of adverse events in patients admitted to a Canadian teaching hospital. CMAJ 2004, 170, 1235–1240. [Google Scholar] [CrossRef] [Green Version]
- Badgery-Parker, T.; Pearson, S.A.; Dunn, S.; Elshaug, A.G. Measuring Hospital-Acquired Complications Associated With Low-Value Care. JAMA Intern. Med. 2019, 179, 499–505. [Google Scholar] [CrossRef] [PubMed]
- Kleinert, S.; Horton, R. From universal health coverage to right care for health. Lancet 2017, 390, 101–102. [Google Scholar] [CrossRef]
- De Hert, M.; Correll, C.U.; Bobes, J.; Cetkovich-Bakmas, M.; Cohen, D.A.N.; Asai, I.; Detraux, J.; Gautam, S.; Möller, H.J.; Ndetei, D.M.; et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011, 10, 52–77. [Google Scholar] [CrossRef]
- Lonchampt, S.; Gerber, F.; Aubry, J.M.; Desmeules, J.; Kosel, M.; Besson, M. Prevalence of Polypharmacy and Inappropriate Medication in Adults With Intellectual Disabilities in a Hospital Setting in Switzerland. Front. Psychiatry 2021, 12, 614825. [Google Scholar] [CrossRef] [PubMed]
- O’Dwyer, M.; McCallion, P.; McCarron, M.; Henman, M. Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: A neglected area of research. Ther. Adv. Drug Saf. 2018, 9, 535–557. [Google Scholar] [CrossRef] [Green Version]
- Antochi, R.; Stavrakaki, C.; Emery, P.C. Psychopharmacological treatments in persons with dual diagnoses of psychiatric disorders and developmental disabilities. Postgrad. Med. J. 2003, 79, 139–146. [Google Scholar] [CrossRef] [Green Version]
- AlMutairi, H.; O’Dwyer, M.; McCarron, M.; McCallion, P.; Henman, M.C. The use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational study. Saudi Pharm. J. 2018, 26, 1012–1021. [Google Scholar] [CrossRef] [PubMed]
- Laudisio, A.; Antonelli Incalzi, R.; Gemma, A.; Giovannini, S.; Lo Monaco, M.R.; Vetrano, D.L.; Padua, L.; Bernabei, R.; Zuccalà, G. Use of proton-pump inhibitors is associated with depression: A population-based study. Int. Psychogeriatr. 2018, 30, 153–159. [Google Scholar] [CrossRef] [PubMed]
- Giovannini, S.; Macchi, C.; Liperoti, R.; Laudisio, A.; Coraci, D.; Loreti, C.; Vannetti, F.; Onder, G.; Padua, L.; Mugello Study Working Group. Association of Body Fat with Health-Related Quality of Life and Depression in Nonagenarians: The Mugello Study. J. Am. Med. Dir. Assoc. 2019, 20, 564–568. [Google Scholar] [CrossRef] [PubMed]
- Carfì, A.; Liperoti, R.; Fusco, D.; Giovannini, S.; Brandi, V.; Vetrano, D.L.; Meloni, E.; Mascia, D.; Villani, E.R.; Manes Gravina, E.; et al. Bone mineral density in adults with Down syndrome. Osteoporos. Int. 2017, 28, 2929–2934. [Google Scholar] [CrossRef] [PubMed]
- Aibar, C.; Aranaz, J.M.; Gracía-Montero, J.L.; Mareca, R. Research on patient safety: Needs and perpectives. Med. Clínica (Barc.) 2008, 131 (Suppl. S3), 12–17. [Google Scholar]
Exposed Cohort | Unexposed Cohort | |||
---|---|---|---|---|
Qualitative Variables | N (%) | N (%) | p-Value 1 | |
Gender | Male | 49 (53.3) | 48 (52.2) | 0.883 |
Female | 43 (46.7) | 44 (47.8) | ||
Service | Medical | 64 (69.6) | 59 (64.1) | 0.709 |
Surgical | 26 (28.3) | 30 (32.6) | ||
ICU | 2 (2.2) | 3 (3.3) | ||
Disability | Intellectual Disability | 48 (52.2) | - | - |
ICP | 24 (26.1) | |||
Down Syndrome | 16 (17.4) | |||
Autism | 4 (4.3) | |||
Percentage of Disability | ≥70% disability | 71 (77.2) | 72 (78.3) | 0.883 |
≥80% disability | 21 (22.8) | 20 (21.7) | ||
Disability Grading | Grade I | 10 (10.9) | 13 (14.1) | 0.790 |
Grade II | 72 (78.3) | 70 (76.1) | ||
Grade III | 10 (10.9) | 9 (9.8) | ||
Quantitative Variables | Mean (±SD) | Mean (±SD) | p-Value 2 | |
Age | 50.5 (±17.7) | 53.6 (±18.1) | 0.252 | |
Length of Stay | 16.0 (±40.9) | 12.5 (±21.3) | 0.478 | |
Admissions Count | 2.4 (±1.8) | 3.5 (±3.6) | 0.007 |
Intrinsic RF | Extrinsic RF | ||||||||
---|---|---|---|---|---|---|---|---|---|
Exp. Coh. N (%) | Unexp. Coh. N (%) | p-Value * | RR (95% CI) | Exp. Coh n (%) | Unexp. Coh. N (%) | p-Value * | RR (95% CI) | ||
Coma | 18 (19.6) | 14 (15.2) | 0.437 | 1.155 (0.817–1.634) | Open urinary catheter | - | - | - | - |
Renal failure | 17 (18.5) | 11 (12.0) | 0.218 | 1.263 (0.899–1.774) | Closed urinary catheter | 32 (34.8) | 27 (29.3) | 0.430 | 1.130 (0.840–1.521) |
Diabetes | 18 (19.6) | 14 (15.2) | 0.437 | 1.155 (0.817–1.634) | Peripheral venous catheter | 76 (82.6) | 76 (82.6) | >0.999 | 1.000 (0.683–1.464) |
Neoplasia | 4 (4.3) | 13 (14.1) | 0.022 * | 0.447 (0.187–0.882) | Arterial catheter | 4 (4.3) | 4 (4.3) | >0.999 | 1.000 (0.492–2.031) |
Immunodeficiency | 2 (2.2) | 8 (8.7) | 0.051 | 0.387 (0.111–1.347) | Peripherally inserted central catheter | 4 (4.3) | 6 (6.5) | 0.515 | 0.791 (0.365–1.714) |
COPD | 9 (9.8) | 8 (8.7) | 0.799 | 1.065 (0.663–1.710) | Central venous catheter | 6 (6.5) | 7 (7.6) | 0.774 | 0.918 (0.501–1.682) |
Neutropenia | 3 (3.3) | 2 (2.2) | 0.650 | 1.207 (0.581–2.506) | Umbilical catheter (vein) | - | - | - | - |
Hepatic cirrhosis | 3 (3.3) | 4 (4.3) | 0.700 | 0.852 (0.358–2.030) | Umbilical catheter (artery) | - | - | - | - |
Drug addiction | - | 7 (7.6) | 0.007 * | - | Parenteral nutrition | 4 (4.3) | 3 (3.3) | 0.700 | 1.149 (0.595–2.220) |
Obesity | 5 (5.4) | 5 (5.4) | >0.999 | 1.000 (0.529–1.891) | Enteral nutrition | - | 2 (2.2) | 0.155 | - |
Hypoalbuminemia | 19 (20.7) | 14 (15.2) | 0.337 | 1.191 (0.851–1.667) | Nasogastric tuve | 7 (7.6) | 7 (7.6) | >0.999 | 1.000 (0.580–1.725) |
Pressure ulcer | 3 (3.3) | 2 (2.2) | 0.650 | 1.207 (0.581–2.506) | Tracheostomy | - | - | - | - |
Malformations | 6 (6.5) | 3 (3.3) | 0.305 | 1.357 (0.834–2.205) | Mechanic ventilation | 3 (3.3) | 5 (5.4) | 0.470 | 0.742 (0.300–1.836) |
Heart failure | 5 (5.4) | 6 (6.5) | 0.756 | 0.904 (0.465–1.756) | Immunosuppressive therapy | 1 (1.1) | 2 (2.2) | 0.560 | 0.663 (0.133–3.306) |
Coronary heart disease | 6 (6.5) | 6 (6.5) | >0.999 | 1.000 (0.557–1.795) | Prior institutionalisation | 29 (31.5) | 3 (3.3) | <0.001 * | 2.187 (1.756–2.723) |
Hypertension | 18 (19.6) | 21 (22.8) | 0.588 | 0.904 (0.622–1.315) | Substance abuse | 10 (19.9) | 33 (35.9) | <0.001 * | 0.400 (0.228–0.701) |
Sum of IRF (mean ± SE) | 1.5 (±1.5) | 1.5 (±1.7) | 0.928 | Sum of ERF (mean ± SE) | 1.9 (±1.3) | 1.9 (±1.4) | 0.958 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alonso-Sardón, M.; Sáez-Lorenzo, M.; Chamorro, A.J.; Fernández-Martín, L.C.; Iglesias-de-Sena, H.; González-Núñez, V.; Santos-Sánchez, J.Á.; Carbonell, C.; Lorenzo-Gómez, M.F.; Mirón-Canelo, J.A. Adverse Effects in Patients with Intellectual and Developmental Disabilities Hospitalized at the University Clinical Hospital. J. Pers. Med. 2022, 12, 1898. https://doi.org/10.3390/jpm12111898
Alonso-Sardón M, Sáez-Lorenzo M, Chamorro AJ, Fernández-Martín LC, Iglesias-de-Sena H, González-Núñez V, Santos-Sánchez JÁ, Carbonell C, Lorenzo-Gómez MF, Mirón-Canelo JA. Adverse Effects in Patients with Intellectual and Developmental Disabilities Hospitalized at the University Clinical Hospital. Journal of Personalized Medicine. 2022; 12(11):1898. https://doi.org/10.3390/jpm12111898
Chicago/Turabian StyleAlonso-Sardón, Montserrat, María Sáez-Lorenzo, Antonio Javier Chamorro, Luz Celia Fernández-Martín, Helena Iglesias-de-Sena, Verónica González-Núñez, José Ángel Santos-Sánchez, Cristina Carbonell, María Fernanda Lorenzo-Gómez, and José Antonio Mirón-Canelo. 2022. "Adverse Effects in Patients with Intellectual and Developmental Disabilities Hospitalized at the University Clinical Hospital" Journal of Personalized Medicine 12, no. 11: 1898. https://doi.org/10.3390/jpm12111898
APA StyleAlonso-Sardón, M., Sáez-Lorenzo, M., Chamorro, A. J., Fernández-Martín, L. C., Iglesias-de-Sena, H., González-Núñez, V., Santos-Sánchez, J. Á., Carbonell, C., Lorenzo-Gómez, M. F., & Mirón-Canelo, J. A. (2022). Adverse Effects in Patients with Intellectual and Developmental Disabilities Hospitalized at the University Clinical Hospital. Journal of Personalized Medicine, 12(11), 1898. https://doi.org/10.3390/jpm12111898